Cullinan Therapeutics, Inc. (Nasdaq: CGEM) announced it received feedback from the U.S. Food and Drug Administration following an End-of-Phase 1 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE